Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion

Published:2019-02 Issue:3 Volume:199 Page:390-392
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Chapman Kenneth R.¹,Hurst John R.²,Fogel Robert B.³,Pfister Pascal⁴,Kostikas Konstantinos⁴,Wedzicha Jadwiga A.⁵⁶

Affiliation:

1. University of TorontoToronto, Ontario, Canada

2. University College LondonLondon, United Kingdom

3. Novartis Pharmaceuticals CorporationEast Hanover, New Jersey

4. Novartis Pharma AGBasel, Switzerland

5. Imperial College LondonLondon, United Kingdomand

6. Editor-in-Chief, AJRCCM

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201809-1776LE

Reference8 articles.

1. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial

2. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis

3. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

4. Efficacy and safety of NVA237versusplacebo and tiotropium in patients with COPD: the GLOW2 study

5. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update;Expert Review of Respiratory Medicine;2021-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3